32411-03-3

Basic information

• Product Name: N-[2-(Dimethylamino)ethyl]-4-methylbenzene-1-sulfonamide
• Synonyms: N-[2-(Dimethylamino)ethyl]-4-methylbenzene-1-sulfonamide;N-[2-(Dimethylamino)ethyl]-4-methylbenzenesulfonamide
• CAS NO: 32411-03-3
• Molecular Formula: C₁₁H₁₈N₂O₂S
• Molecular Weight: 0
• Mol File: 32411-03-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 355.2°C at 760 mmHg
• Flash Point: 168.6°C
• Appearance: /
• Density: 1.137g/cm³
• Vapor Pressure: 3.18E-05mmHg at 25°C
• Refractive Index: 1.534
• CAS DataBase Reference: N-[2-(Dimethylamino)ethyl]-4-methylbenzene-1-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(Dimethylamino)ethyl]-4-methylbenzene-1-sulfonamide(32411-03-3)
• EPA Substance Registry System: N-[2-(Dimethylamino)ethyl]-4-methylbenzene-1-sulfonamide(32411-03-3)

Safety Data

• Hazardous Substances Data: 32411-03-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H18N2O2S/c1-10-4-6-11(7-5-10)16(14,15)12-8-9-13(2)3/h4-7,12H,8-9H2,1-3H3

Upstream product

• 108-00-9 N,N-dimethylethylenediamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 824-79-3 sodium 4-methylbenzenesulfinate 
• 110-70-3 N,N`-dimethylethylenediamine 
• 3634-89-7 N-(p-toluenesulfonyl)aziridine 
• 124-40-3 dimethyl amine 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 18522-92-4 sodium p-toluenesulfonamide 

Downstream Products

• 728039-31-4 [(η⁶-p-cymene)Ru(N-(2-(dimethylamino)ethyl)-4-methylbenzenesulfonamide)Cl] 

Relevant articles and documents

Effect of sulfonamidoethylenediamine substituents in RuII arene anticancer catalysts on transfer hydrogenation of coenzyme NAD+ by formate

A series of neutral pseudo-octahedral RuII sulfonamidoethylenediamine complexes [(η6-p-cym)Ru(N,N′)Cl] where N,N′ is N-(2-(R1,R2-amino)ethyl)-4-toluenesulfonamide (TsEn(R1,R2)) R1,R2 = Me,H (1); Me,Me (2); Et,H (3); benzyl,H (Bz, 4); 4-fluorobenzyl,H (4-F-Bz, 5) or naphthalen-2-ylmethyl,H (Naph, 6), were synthesised and characterised including the X-ray crystal structure of 3. These complexes catalyse the reduction of NAD+ regioselectively to 1,4-NADH by using formate as the hydride source. The catalytic efficiency depends markedly on the steric and electronic effects of the N-substitutent, with turnover frequencies (TOFs) increasing in the order: 1 -1 for 4 with a 95% yield of 1,4-NADH. The reduction rate was highest between pH? (deuterated solvent) 6 and 7.5 and improved with an increase in formate concentration (TOF of 18.8 h-1, 140 mM formate). The calculations suggested initial substitution of an aqua ligand by formate, followed by hydride transfer to RuII and then to NAD+, and indicated specific interactions between the aqua complex and both NAD+ and NADH, the former allowing a preorganisation involving interaction between the aqua ligand, formate anion and the pyridine ring of NAD+. The complexes exhibited antiproliferative activity towards A2780 human ovarian cancer cells with IC50 values ranging from 1 to 31 μM, the most potent complex, [(η6-p-cym)Ru(TsEn(Bz,H))Cl] (4, IC50 = 1.0 ± 0.1 μM), having a potency similar to the anticancer drug cisplatin. Co-administration with sodium formate (2 mM), increased the potency of all complexes towards A2780 cells by 20-36%, with the greatest effect seen for complex 6.

Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences

The compositions of the present invention comprise one or more palladium bound ligands that are covalently bonded to inorganic or organic solid supports. These palladium bound ligands bonded to solid supports can be used for single heterocyclic amine base separation, or can be used to separate nucleotide chain containing specific sequences from other nucleotides or nucleotide chains. In one aspect of the invention, each ligand present is individually complexed to a single Pd(II) ion. If there are from 2 to 4 ligands present in the composition, then each ligand present must be separated from the other ligands by at least 3 atoms, preferably from 3 to 20 carbon atoms or equivalent spacing.